Measurement of branching fractions and CP violation for charmless charged two-body B decays at LHCb

Charmless charged two-body B decays are sensitive probes of the CKM matrix, that parameterize CP violation in the Standard Model (SM), and have the potential to reveal the presence of New Physics. The framework of CP violation within the SM, the role of the CKM matrix, with its basic formalism, and the current experimental status are presented. The theoretical tools commonly used to deal with hadronic B decays and an overview of the phenomenology of charmless two-body B decays are outlined. LHCb is one of the four main experiments operating at the Large Hadron Collider (LHC), devoted to the measurement of CP violation and rare decays of charm and beauty hadrons. The LHCb detector is described, focusing on the technologies adopted for each sub-detector and summarizing their performances. The status-of-the-art of the LHCb measurements with charmless two-body B decays is then presented. Using the 37/pb of integrated luminosity collected at sqrt(s) = 7 TeV by LHCb during 2010, the direct CP asymmetries ACP(B0 -> Kpi) = −0.074 +/- 0.033 +/- 0.008 and ACP(Bs -> piK) = 0.15 +/- 0.19 +/- 0.02 are measured. Using 320/pb of integrated luminosity collected during 2011 these measurements are updated to ACP(B0 -> Kpi) = −0.088 +/- 0.011 +/- 0.008 and ACP(Bs -> piK) = 0.27 +/- 0.08 +/- 0.02. In addition, the branching ratios BR(B0 -> K+K-) = (0.13+0.06-0.05 +/- 0.07) x 10^-6 and BR(Bs -> pi+pi-) = (0.98+0.23-0.19 +/- 0.11) x 10^-6 are measured. Finally, using a sample of 370/pb of integrated luminosity collected during 2011, the relative branching ratios BR(B0 -> pi+pi-)/BR(B0 -> Kpi) = 0.262 +/- 0.009 +/- 0.017, (fs/fd)BR(Bs -> K+K-)/BR(B0 -> Kpi)=0.316 +/- 0.009 +/- 0.019, (fs/fd)BR(Bs -> piK)/BR(B0 -> Kpi) = 0.074 +/- 0.006 +/- 0.006 and BR(Lambda_b -> ppi)/BR(Lambda_b -> pK)=0.86 +/- 0.08 +/- 0.05 are determined.

Ultra-hypofractionated stereotactic radiotherapy for prostate cancer in 5 fractions: current evidences and our clinical experience

AIMS: The present is a retrospective evaluation of acute genito-urinary (GU) and gastro-intestinal (GI) toxicity, in addition to biochemical recurrence rate in 57 prostate cancer patients treated at our Institution with ultra-hypofractionated RT (UHRT) schedule. METHODS: From January 2021 to December 2022 we have treated 57 patients with prostate cancer, using an UHRT scheme of 5-fractions every other day for a total dose delivered of 36.25 Gy, according to the PACE-B trial treatment schedule. Good urinary function, assessed by International Prostate Symptom Score (IPSS), were required. The simulation CT scans were acquired in supine position and fused with MRI for CTVs definition for every patient. Each treatment was performed by Accuray's TomoTherapy with daily IGRT. The evaluation of the set-up was very restrictive before daily treatment delivery. RESULTS: According to RTOG toxicity scale, the acute GU toxicity at 3 months from RT, GU toxicity was G0 for 30 patients (52.6%), G1 for 26 (45.6%) and G2 for one only (1.75%); rectal toxicity was G0 for 56 patients (98.25%) and G1 for one only (1.75%). The median follow-up (FU) was 9 months (2-24 months). In the following FU months, we observed progressively lower urinary and rectal toxicity, except for one patient who showed G2 GU toxicity at 12 months. All but one patient had a progressive PSA value decrease. CONCLUSIONS: In our experience, UHRT appears to be safe and well tolerated even without the use of rectal spacer devices. A longer FU is necessary to evaluate late toxicity and disease control rate.